1 Center of Gastrointestinal Disease, Ersta Hospital and Karolinska Institute, 2 Pediatric Endocrinology Unit, Department of Woman and Child Health, and 3 Department of Endocrinology and Diabetes, Karolinska Hospital, Stockholm, Sweden
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have studied the effects
of insulin on the bioavailability of insulin-like growth factor (IGF) I
in insulin-resistant patients after surgery. Serum levels of total
IGF-I (tIGF-I), free IGF (fIGF)-I, fIGF-II, and IGF-binding protein
(IGFBP) 1 and IGFBP-3 proteolytic activity (IGFBP-3-PA), determined on
the day before surgery and on the 1st postoperative day, were related
to insulin sensitivity measured by a hyperinsulinemic, normoglycemic
clamp. Before surgery, the decreased tIGF-I (P < 0.05)
in response to insulin infusion was accompanied by an 18% reduction of
IGFBP-1 (P < 0.001), while IGFBP-3-PA remained
unchanged. Levels of fIGF-I and fIGF-II were not changed by insulin
infusions. After surgery, IGFBP-3-PA increased (P < 0.05) during insulin infusion, and this was associated with an increase
in tIGF-I (P < 0.001) and fIGF-I (P < 0.01), while no significant change was found in fIGF-II. The reduction
in IGFBP-1 in response to insulin infusion was not affected by surgery.
The change in IGFBP-3-PA during insulin infusion after surgery was
related to the corresponding change in fIGF-I (r2 = 0.26, P < 0.05) and
postoperative insulin sensitivity (r2 = 0.22, P < 0.05). These data suggest that increased
IGFBP-3-PA during insulin infusion after surgery governs the increased
levels of fIGF-I, while insulin-induced suppression of IGFBP-1 was not affected by surgery. We propose that, in catabolic, postoperative patients, increased levels of insulin from exogenous or, possibly, endogenous sources (nutritionally induced) may be a signal to increase
IGF-I bioavailability by increased expression of IGFBP-3-PA to
counteract further deterioration in glucose metabolism.
glucose homeostasis; insulin resistance; insulin-like growth factor bioavailability; glucose clamp technique
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
DURING THE PAST YEARS, it has become clear that the catabolic change in metabolism after trauma is not solely regulated by the catabolic stress hormones but also by a complex set of changes in the anabolic regulators of metabolism. Thus marked reductions in the levels of insulin-like growth factor (IGF) I have been reported to occur after burn trauma (24), in critical illness (35), and after major surgical procedures (31). However, to establish the biological significance of IGF-I levels in serum, the simultaneous changes in the IGF-binding proteins (IGFBP) must be considered.
Levels of IGFBP-1 are increased after different types of trauma, such as burn injury (24) and surgery (30), and this increase may inhibit IGF-I activity by keeping the hormone bound (22, 23, 33). In healthy subjects, insulin is the main regulator of IGFBP-1 by inhibiting IGFBP-1 production (6). It is not known whether the increase in IGFBP-1 after trauma may be explained by an impaired sensitivity to the inhibitory effect of insulin on IGFBP-1 production or whether other factors, such as an increase in glucagon or cytokines, may further upregulate IGFBP-1 (15, 21, 36). In healthy subjects, most IGF-I is bound to IGFBP-3 and an acid-labile subunit in a ternary complex, and <1% is believed to be present in the free form. IGFBP-3 proteolytic activity (IGFBP-3-PA) reduces the affinity of IGF-I to IGFBP-3, and this has been shown to increase IGF-I bioactivity in vitro (5). IGFBP-3-PA has been shown to increase in a number of catabolic conditions, such as non-insulin-dependent diabetes mellitus (1), severe illness (8), and after surgery (7). In a recent study in surgical patients, no postoperative decrease was found in free IGF (fIGF)-I, despite decreased levels of total IGF (tIGF)-I while IGFBP-3-PA increased, suggesting a role for IGFBP-3-PA in the maintenance of fIGF-I after surgery (31). Moreover, we recently demonstrated that IGFBP-3-PA was increased in response to insulin infusion during a hyperinsulinemic, normoglycemic clamp performed on the day after abdominal surgery, suggesting that insulin may affect IGF-I bioavailability by induction of IGFBP-3-PA in postoperative patients (4).
The aims of the present study were to investigate how IGF-I bioavailability was affected by an insulin challenge after elective surgery and whether the changes were dependent on insulin sensitivity. Two different methods for measuring fIGF-I, ultracentrifugation and immunoradiometric assay (IRMA), were used, since these methods have been shown to provide slightly different results depending on whether changes in IGF-I availability were accomplished by changes in IGFBP-1 or IGFBP-3-PA (11, 14). The insulin challenge was performed as a hyperinsulinemic, normoglycemic clamp in patients before surgery and in the same patients with reduced insulin sensitivity on the day after surgery. The responses of tIGF-I, fIGF-I, fIGF-II, and IGFBP-1 were compared with previously reported changes in IGFBP-3-PA in an attempt to estimate changes in IGF bioavailability. We have demonstrated that, in the insulin-resistant state after surgery, insulin-induced IGFBP-3-PA is associated with an increase in levels of fIGF-I. In addition, we report that the inhibition of IGFBP-1 by insulin is largely intact in the insulin-resistant state after surgery.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Patients.
Eighteen patients scheduled for elective abdominal surgery were
studied. Their surgical diagnoses (although not in an acute inflammatory stage of the disease) were inflammatory bowel disease (n = 8) and diverticular disease of the sigmoid colon
(n = 6). The remaining subjects underwent surgery for
hereditary colon polyposis (n = 3) and a hypernephroma
of the right kidney (n = 1). The surgical and
anesthetic procedures, as well as the perioperative care of the
patients, have been presented elsewhere (4). We also
previously reported data on insulin sensitivity and changes in
IGFBP-3-PA and the circulating forms of IGFBP-3 (4).
Briefly, eight patients (45 ± 5 yr old, 24 ± 1 kg/m2 body mass index, 2 men and 6 women) were given 800 ml
of an isosmolar carbohydrate-rich oral glucose load (12.5%
carbohydrates; Numico, Zoetermeer, The Netherlands) on the evening
before surgery and an additional 400 ml 2 h before the induction of
anesthesia (OGL group). Ten patients (45 ± 4 yr old, 24 ± 1 kg/m2 body mass index, 4 men and 6 women) underwent surgery
after fasting overnight (Fast group). All patients were subjected to a
hyperinsulinemic, normoglycemic (4.5 mM), two-step clamp (insulin
infusion rates 0.3 and 0.8 mU · kg
1 · min
1 for 120 min
at each level) twice after fasting overnight, once on the day before
and once on the day after surgery. The glucose infusion rate required
to maintain normoglycemia during the last 60 min of the clamp was used
as a measure of insulin sensitivity (29). The study
protocol was approved by the Institutional Ethical Committee at the
Karolinska Hospital, and the subjects gave their informed consent
before entering the study.
Sampling and analysis.
Arterialized blood from a heated hand vein was collected as described
elsewhere (34). Glucose was sampled at baseline and at
least every 10 min during clamping and was measured immediately on
collection using the glucose oxidase method (Yellow Springs Instruments, Yellow Springs, OH) (17). Serum insulin was
analyzed by radioimmunoassay (RIA) using an antibody developed in our
laboratory (13). Serum IGFBP-1 (28) was
analyzed using RIA methods. Serum tIGF-I was extracted with acid
ethanol and then analyzed by an RIA technique developed in our own
laboratory, with des-(1-3)-IGF-I as a radioligand to
prevent interaction of IGFBPs (3). IGFBP-3-PA was
determined as the ability of serum to degrade 125I-labeled
human recombinant glycosylated IGFBP-3 as reported elsewhere (4), on the basis of the original report by Lamson et al.
(20). Serum samples were allowed to clot, while plasma
samples were centrifuged immediately at 4°C at 3,000 rpm for 10 min
and stored at 20°C for subsequent batch analyses. tIGF-I, fIGF-I,
fIGF-II, and IGFBP-3-PA were sampled immediately before and after 210 min of insulin infusion. Insulin and IGFBP-1 were sampled at baseline and every 30 min during the clamps (±0, 60, 90, 120, 180, 210, and 240 min). In comparisons with other parameters, we used insulin and IGFBP-1
sampled at the corresponding time of the study.
Statistics. Values are means ± SE. Statistical significance was accepted at P < 0.05 using a two-way analysis of variance for repeated measurements and Student's t-test for post hoc testing. Correlations were calculated using simple regression.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
After surgery, glucose infusion rate during clamps decreased by
50-60% compared with the preoperative situation in the OGL and
Fast groups (P = 0.016 and P < 0.0001, respectively), and infusion of insulin after surgery was associated
with an increased IGFBP-3-PA, with no difference between the OGL and
Fast groups (4). Before surgery, an 18% decrease in
IGFBP-1 (P < 0.001) was demonstrated in response
to insulin infusion (0.8 mU · kg1 · min
1; Fig.
1). No change was found in IGFBP-3-PA
(Fig. 1). The levels of tIGF-I decreased in response to 210 min of
insulin infusion (P < 0.05), while no change was found
in fdIGF-I by IRMA or fdIGF-I and fdIGF-II by ultrafiltration.
|
After surgery, there was an increase in IGFBP-3-PA (P < 0.001) in response to 210 min of insulin infusion compared with baseline, as reported elsewhere (4). This was associated with a simultaneous 34% increase in fdIGF-I by IRMA (P < 0.005). Although the changes in fdIGF-I in response to insulin after surgery were not different regardless of whether fdIGF-I was analyzed using ultrafiltration or IRMA (P = 0.51), the apparent 54% increase in fdIGF-I, as determined by ultrafiltration, failed to reach statistical significance (P = 0.15). No significant changes were found in tIGF-I (P = 0.36) or fdIGF-II (P = 0.98) in response to 210 min of insulin infusion after surgery.
The responses to insulin infusions before and after surgery were quite
different for tIGF-I (P < 0.0001), fdIGF-I by
ultrafiltration (P < 0.01), and fdIGF-I by IRMA
(P < 0.005), while no significant difference was found
for fdIGF-II by ultrafiltration (Fig. 1). The 17% decrease in IGFBP-1
(P < 0.05; Fig. 1) in response to insulin infusion
after surgery was not different from the corresponding changes at the
preoperative clamp (P = 0.98). During insulin infusion, the changes in IGFBP-1 over time were similar before and after surgery
(Fig. 2). The changes in the reported
parameters did not differ between the OGL and Fast groups at any time
(P > 0.4). Therefore, the data are presented as
means ± SE for all patients regardless of whether they received
an oral glucose load before surgery.
|
After surgery, the individual increases in IGFBP-3-PA in response to
insulin correlated with fdIGF-I measured by ultrafiltration (r2 = 0.23, P < 0.05; Fig.
3) and with fdIGF-I by IRMA
(r2 = 0.26, P < 0.05; Fig.
3), but not significantly with fdIGF-II (P = 0.19). The
increase in fdIGF-I by ultrafiltration in response to insulin after
surgery correlated with the simultaneous changes in fdIGF-II
(r2 = 0.66, P = 0.0001) but
not significantly with fdIGF-I by IRMA (r2 = 0.16, P = 0.098). Preoperative insulin sensitivity
did not correlate with any of the measured variables (P > 0.3). In contrast, postoperative insulin sensitivity correlated with
the change in IGFBP-3-PA in response to insulin after surgery
(r2 = 0.22, P < 0.05;
Fig. 4).
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This is the first report suggesting that insulin may regulate fdIGF-I by modulating IGFBP-3-PA in the insulin-resistant state after surgery. We previously reported that insulin infusions were associated with an increase in IGFBP-3-PA after surgery (4). We now demonstrate an association between increased IGFBP-3-PA during insulin infusions and simultaneously increased circulating levels of fdIGF-I after surgery. With the use of two different assays to assess IGF bioavailability, an increase in fdIGF-I in response to an insulin challenge on the day after surgery has been demonstrated. This increase was not present before surgery. IGFBP-1, which may regulate IGF-I bioavailability in insulin-sensitive healthy subjects (10), proved not to be related to IGF-I after surgery and seems to have less impact on fdIGF-I in the insulin-resistant state that has developed on the day after surgery. Interestingly enough, whereas insulin-induced changes in IGFBP-3-PA were related to postoperative insulin sensitivity, insulin suppression of IGFBP-1 was not affected by surgery.
The extent to which IGF-I contributes to glucose homeostasis in the postoperative situation is not known. Because IGF-I activity is modulated by several IGFBPs, it is difficult to study the bioactivity of IGF-I at the tissue level in vivo. However, several previous studies indicate that IGF-I may have effects on glucose homeostasis in healthy subjects. IGF-I and insulin stimulated glucose transport similarly on a molar basis in human skeletal muscle strips (9). Furthermore, when IGF-I or insulin was infused during normoglycemic clamps in doses providing the same glucose infusion rates required to maintain normoglycemia, IGF-I was more efficient than insulin in increasing glucose uptake and decreasing protein breakdown (19). In addition, levels of fIGF-I were related to insulin sensitivity, as measured by the minimal model (27). Although insulin sensitivity was related to changes in IGFBP-3-PA in the present study, which indicates a relationship between bioactive IGF-I and insulin sensitivity, no significant relationship was found between fIGF-I and insulin sensitivity. This may be explained simply by the small size of the study and the larger variability in the measurements of fdIGF-I compared with IGFBP-3-PA. However, circulating fIGF-I levels may not fully reflect the tissue levels of fIGF-I. Furthermore, IGFBP-3 and/or its fragments may have independent effects on glucose metabolism, none of which were determined in the present study. Furthermore, the present study does not address the question of whether, in addition to insulin resistance, there is resistance to IGF-I-induced glucose uptake in skeletal muscle after surgery, as reported in patients with type 2 diabetes (9).
Reduced tIGF-I after surgery has been suggested to be a result of impaired generation of IGF-I by growth hormone (GH) due to GH receptor "uncoupling" (29). Although increased IGFBP-3-PA results in increased concentrations of circulating fIGF-I, the ternary complex containing IGF, proteolyzed IGFBP-3, and acid-labile subunits has been reported to remain intact (32). Thus it appears that, despite increased IGFBP-3-PA, only a minor fraction of tIGF-I is allowed to dissociate from the main circulating IGF-I stores. It is therefore likely that a decreased IGF-I production rate, rather than increased IGFBP-3-PA, contributes to the substantial reduction of tIGF-I concentrations at baseline after surgery. This view is supported by the finding of increased tIGF-I concentrations in pregnant women, despite the complete fragmentation of IGFBP-3 in the ternary complex due to IGFBP-3 proteolysis (12, 16). IGFBP-3 proteolysis may therefore be an efficient mechanism for increasing IGF-I bioavailability and, thereby, allowing anabolic processes such as glucose and amino acid uptake, as well as tissue repair, to occur without markedly increasing clearance of the IGF-I tissue stores. This is also supported by our present findings that tIGF-I levels were unchanged during insulin infusion after surgery, despite an increase in IGFBP-3-PA. Such a mechanism would be sufficient to support anabolic events for a limited period of time until insulin sensitivity and IGF-I production are restored. Further studies are needed to determine whether the restoration of insulin sensitivity is also the signal that shuts off IGFBP-3 proteolysis.
Levels of IGFBP-1 increase even after a brief period of fasting (2). In the present study, the patients were semistarved before the postoperative measurement as a result of routine clinical treatment with hypocaloric nutrition (50-75 g glucose) during the first 24 h after the operation. Recently, we studied healthy subjects subjected to the same protocol used in this study before and after 24 h of combined treatment with hypocaloric nutrition (50 g glucose) and bed rest to determine the importance of these factors for the changes occurring after surgery (25). In that study, baseline levels of IGFBP-1 increased twofold after a 24-h period of bed rest and hypocaloric nutrition, possibly as a result of a simultaneous drop in insulin levels. In these subjects, IGFBP-1 was rapidly reduced in response to insulin infusion, indicating a normal response to insulin. In the same subjects, 24 h of hypocaloric nutrition and bed rest had no effect on IGFBP-3-PA (unpublished data). Because the change in IGFBP-3-PA appears to be one of the main determinants of IGF bioavailability at 1 day after surgery, hypocaloric nutrition and bed rest in connection with surgery are not likely to be important contributors to the above-mentioned postoperative changes in IGF-I bioavailability.
Although baseline levels of IGFBP-1 were elevated after surgery, IGFBP-1 was reduced similarly in response to insulin infusion before and after surgery. This indicates a normal sensitivity to insulin in the hepatic tissues. This is in line with our previous findings that hepatic insulin sensitivity is not affected after uncomplicated abdominal surgery (26). Increased baseline levels of IGFBP-1 postoperatively may be due to increased levels of glucagon, cytokines, or other factors that may stimulate IGFBP-1 production or reduce clearance (15, 21, 36).
In conclusion, increased IGFBP-3-PA in response to insulin infusions was associated with increased levels of fIGF-I after surgery, while no relationship was found between fIGF-I and IGFBP-1 before or after surgery. The insulin-induced increase in IGFBP-3-PA was more pronounced in more insulin-resistant patients, while the suppression of IGFBP-1 in response to an insulin infusion was not affected by surgery. These observations strongly suggest that insulin is involved in the modulation of IGF-I bioavailability through the induction of IGFBP-3-PA after surgery. This may be one important anabolic effect of insulin in postoperative patients.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Lotta Hylén and Cajsa Almström for excellent technical assistance with the clamps and Jan Frystyk and Christian Skjærbæk (Medical Research Laboratory, Aarhus University Hospital, Aarhus, Denmark) for the determinations of fdIGFs and for helpful comments on the manuscript.
![]() |
FOOTNOTES |
---|
This work was supported by grants from the Karolinska Institute, Swedish Medical Research Council Grants 11634, 09101, and 4224, the Swedish Diabetes Association, Fredrik and Ingrid Thüring's Foundation, the Swedish Society of Medicine, Torsten and Ragnar Söderberg's Foundation, Wera Ekström's Foundation, Swedish Freemasons' Foundation, Märta and Gunnar V. Philipson's Foundation, and Numico Corporate Research (Zoethermeer, The Netherlands).
Address for reprint requests and other correspondence: J. Nygren, Center of Gastrointestinal Disease, Ersta Hospital, Box 4622, SE-116 91 Stockholm, Sweden (E-mail: jonas.nygren{at}ersta.se).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 19 September 2000; accepted in final form 16 April 2001.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Bang, P,
Brismar K,
and
Rosenfeld RG.
Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in non-insulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the ~130- to 150-kDa ternary complex.
J Clin Endocrinol Metab
78:
1119-1127,
1994[Abstract].
2.
Bang, P,
Brismar K,
Rosenfeld RG,
and
Hall K.
Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with non-insulin-dependent diabetes mellitus vs. healthy nonobese and obese subjects.
J Clin Endocrinol Metab
78:
960-967,
1994[Abstract].
3.
Bang, P,
Eriksson U,
Sara V,
Wivall IL,
and
Hall K.
Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand.
Acta Endocrinol
124:
620-629,
1991[ISI][Medline].
4.
Bang, P,
Nygren J,
Carlsson-Skwirut C,
Thorell A,
and
Ljungqvist O.
Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity.
J Clin Endocrinol Metab
83:
2509-2515,
1998
5.
Blat, C,
Villaudy J,
and
Binoux M.
In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells.
J Clin Invest
93:
2286-2290,
1994[ISI][Medline].
6.
Brismar, K,
Fernqvist-Forbes E,
Wahren J,
and
Hall K.
Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes.
J Clin Endocrinol Metab
79:
872-878,
1994[Abstract].
7.
Cwyfan Hughes, SC,
Cotterill AM,
Molloy AR,
Cassell TB,
Braude N,
Hinds CJ,
Wass JA,
and
Holly JM.
The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery.
J Endocrinol
135:
135-145,
1992[Abstract].
8.
Davies, SC,
Wass JA,
Ross RJ,
Cotterill AM,
Buchanan CR,
Coulson VJ,
and
Holly JM.
The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness.
J Endocrinol
130:
469-473,
1991[Abstract].
9.
Dohm, GL,
Elton CW,
Raju MS,
Mooney ND,
DiMarchi R,
Pories WJ,
Flickinger EG,
Atkinson SM, Jr,
and
Caro JF.
IGF-I-stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM.
Diabetes
39:
1028-1032,
1990[Abstract].
10.
Frystyk, J,
Hussain M,
Skjaerbaek C,
Schmitz O,
Christiansen JS,
Froesch ER,
and
Orskov H.
Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline.
Am J Physiol Endocrinol Metab
273:
E507-E513,
1997
11.
Frystyk, J,
Skjaerbaek C,
Dinesen B,
and
Orskov H.
Free insulin-like growth factors (IGF-I and IGF-II) in human serum.
FEBS Lett
348:
185-191,
1994[ISI][Medline].
12.
Giudice, LC,
Farrell EM,
Pham H,
Lamson G,
and
Rosenfeld RG.
Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity.
J Clin Endocrinol Metab
71:
806-816,
1990[Abstract].
13.
Grill, V,
Pigon J,
Hartling SG,
Binder C,
and
Efendic S.
Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders.
Metabolism
39:
251-258,
1990[ISI][Medline].
14.
Hasegawa, Y,
Hasegawa T,
Fujii K,
Konii H,
Anzo M,
Aso T,
Koto S,
Takada M,
and
Tsuchiya Y.
High ratios of free to total insulin-like growth factor-I in early infancy.
J Clin Endocrinol Metab
82:
156-158,
1997
15.
Hilding, A,
Brismar K,
Thoren M,
and
Hall K.
Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus.
J Clin Endocrinol Metab
77:
1142-1147,
1993[Abstract].
16.
Hossenlopp, P,
Segovia B,
Lassarre C,
Roghani M,
Bredon M,
and
Binoux M.
Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy.
J Clin Endocrinol Metab
71:
797-805,
1990[Abstract].
17.
Hugget, A,
and
Nixon D.
Use of glucose peroxidase and 0-dianisidin in determinations of blood and urinary glucose.
Lancet
2:
368-370,
1957.
18.
Juul, A,
Flyvbjerg A,
Frystyk J,
Muller J,
and
Skakkebaek NE.
Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty.
Clin Endocrinol (Oxf)
44:
515-523,
1996[ISI][Medline].
19.
Laager, R,
Ninnis R,
and
Keller U.
Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans.
J Clin Invest
92:
1903-1909,
1993[ISI][Medline].
20.
Lamson, G,
Giudice LC,
and
Rosenfeld RG.
A simple assay for proteolysis of IGFBP-3.
J Clin Endocrinol Metab
72:
1391-1393,
1991[Abstract].
21.
Lang, CH,
Nystrom GJ,
and
Frost RA.
Regulation of IGF binding protein-1 in Hep G2 cells by cytokines and reactive oxygen species.
Am J Physiol Gastrointest Liver Physiol
276:
G719-G727,
1999
22.
Lewitt, MS.
Role of the insulin-like growth factors in the endocrine control of glucose homeostasis.
Diabetes Res Clin Pract
23:
3-15,
1994[ISI][Medline].
23.
Murphy, LJ.
Overexpression of insulin-like growth factor binding protein-1 in transgenic mice.
Pediatr Nephrol
14:
567-571,
2000[ISI][Medline].
24.
Nygren, J,
Sammann M,
Malm M,
Efendic S,
Hall K,
Brismar K,
and
Ljungqvist O.
Distributed anabolic hormonal patterns in burned patients: the relation to glucagon.
Clin Endocrinol (Oxf)
43:
491-500,
1995[ISI][Medline].
25.
Nygren, J,
Thorell A,
Brismar K,
Karpe F,
and
Ljungqvist O.
Short-term hypocaloric nutrition but not bed rest decreases insulin sensitivity and IGF-I bioavailability in healthy subjects: the importance of glucagon.
Nutrition
13:
945-951,
1997[ISI][Medline].
26.
Nygren, J,
Thorell A,
Efendic S,
Nair KS,
and
Ljungqvist O.
Site of insulin resistance after surgery: the contribution of hypocaloric nutrition and bed rest.
Clin Sci (Colch)
93:
137-146,
1997[ISI][Medline].
27.
Nyomba, BL,
Berard L,
and
Murphy LJ.
Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity.
J Clin Endocrinol Metab
82:
2177-2181,
1997
28.
Povoa, G,
Roovete A,
and
Hall K.
Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid.
Acta Endocrinol
107:
563-570,
1984[ISI][Medline].
29.
Rizza, RA,
Mandarino LJ,
and
Gerich JE.
Dose-response characteristics for effects of insulin on production and utilization of glucose in man.
Am J Physiol Endocrinol Metab
240:
E630-E639,
1981
30.
Ross, RJ,
Miell JP,
Holly JM,
Maheshwari H,
Norman M,
Abdulla AF,
and
Buchanan CR.
Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients.
Clin Endocrinol (Oxf)
35:
361-367,
1991[ISI][Medline].
31.
Skjaerbaek, C,
Frystyk J,
Orskov H,
Kissmeyer-Nielsen P,
Jensen MB,
Laurberg S,
Moller N,
and
Flyvbjerg A.
Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis.
J Clin Endocrinol Metab
83:
2445-2449,
1998
32.
Suikkari, AM,
and
Baxter RC.
Insulin-like growth factor-binding protein-3 is functionally normal in pregnancy serum.
J Clin Endocrinol Metab
74:
177-183,
1992[Abstract].
33.
Taylor, AM,
Dunger DB,
Grant DB,
and
Preece MA.
Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin-dependent diabetes compared with puberty matched controls.
Diabetes Res
9:
177-181,
1988[ISI][Medline].
34.
Thorell, A,
Efendic S,
Gutniak M,
Haggmark T,
and
Ljungqvist O.
Insulin resistance after abdominal surgery.
Br J Surg
81:
59-63,
1994[ISI][Medline].
35.
Timmins, AC,
Cotterill AM,
Hughes SC,
Holly JM,
Ross RJ,
Blum W,
and
Hinds CJ.
Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease.
Crit Care Med
24:
1460-1466,
1996[ISI][Medline].
36.
Tucci, M,
Nygard K,
Tanswell BV,
Farber HW,
Hill DJ,
and
Han VK.
Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells.
J Endocrinol
157:
13-24,
1998